The Value of Pragmatic Randomized Clinical Trials: Strategic Approaches for Real-World Impact

Unlock the advantage of pragmatic trials and improve efficiency and real-world relevance to reduce risk and strengthen regulatory readiness. Join experts for case studies, proven strategies, and a live Q&A session on how pragmatic design drives stronger real-world evidence.

Register Free: https://www.pharmexec.com/pe_w/Pragmatic_Randomized_Clinical_Trials

Event Overview:

This webcast explores how pragmatic clinical trials combine scientific rigor with operational flexibility through trial design and execution, empowering sponsors to reduce trial risk and enhance real-world applicability. Learn how pragmatic clinical trial models can support decision-making—in the clinic and beyond—in today’s competitive environment.

Key Themes:

• Case studies in pragmatic trial design and execution
  
• High-impact real-world evidence to strengthen regulatory submissions, clinical decision making, and influence policy
  
• Live Q&As addressing current challenges in pragmatic trial design and execution
  

Key Learning Objectives:

• Recognize how pragmatic trials strategically overcome sponsor-critical challenges, participant recruitment, and retention
• Combine practical tools and operational expertise to deliver robust, generalizable, real-world evidence that supports regulatory submissions
  
• Apply insights from case studies to accelerate evidence generation and market adoption
  

Who Should Attend:

• Those in clinical operations, medical, and R&D; project managers, pharmaceutical decision-makers, those in biotech, and those part of medical device organizations
  
• Academic investigators and research networks
  
• Clinicians and key opinion leaders (KOLs) shaping the real-world impact of sponsor-backed trials

Speakers

Guillaume Marquis-Gravel, MD, MSc
Interventional Cardiologist
Associate Professor of Clinics
Montreal Heart Institute
Université de Montréal

Dr. Guillaume Marquis-Gravel, MD, MSc, is an interventional cardiologist at the Montreal Heart Institute and an associate professor of clinics at the Université de Montréal. Trained at Duke University in interventional cardiology and clinical research, his work focuses on antithrombotic therapies, coronary artery disease, and revascularization. He has led and contributed to pragmatic trials including ADAPTABLE, NEPTUNE, and PANTHEON, authored over 120 publications, and co-chaired the 2023 Canadian antiplatelet therapy guidelines.

Melissa Stremel, BA, BSc
Director of Operations
Seriant

Melissa Stremel has over 20 years of experience leading global clinical trial operations across phases I–IV and diverse therapeutic areas. Known for her strategic vision and collaborative approach, she has contributed to the approval of numerous treatments in neurology, psychiatry, and rare and infectious diseases. At Seriant, she drives innovation in clinical research, advancing trials to deliver tailored strategies for complex, multinational studies.

Register Free: https://www.pharmexec.com/pe_w/Pragmatic_Randomized_Clinical_Trials